Sort by 'likes'
HIFU for Prostate Cancer Finally Gets the FDA Nod. What to expect.
After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the first high-intensity focused ultrasound (HIFU) device for ablation of prostate tissue. HIFU has already been approved for use in prostate tissue outside…
ASH 2019 Annual Meeting Multiple Myeloma Updates
The 62nd ASH (American Society of Hematology) annual meeting was held in early December 2019. We are talking to Dr Shaji Kumar about new research presented at ASH, including disease-specific treatment updates on multiple myeloma, the role of precision medicine & clinical…
Inherited Gene Mutations in Myeloma and Role of Precision Medicine
Multiple Myeloma is the second most common cancer of the blood and is largely incurable. A recent study has found that a specific gene mutation can increase the risk of developing myeloma six to nine fold. The lead author of…
Targeting Stem Cells in Multiple Myeloma for Improved Outcomes
Multiple myeloma remains incurable despite improved remissions with novel agents. Relapse eventually occurs in the form of drug-resistant disease that carries a dismal prognosis. Relapse is dependent on stem cell functions. We are talking to Dr. William Matsui of Johns…
Total Therapy and Myeloma with UAMS
Total Therapy is the only program in the world which talk about a cure for myeloma. Total Therapy is based on the approach that the best chance of eliminating all disease is at the beginning of treatment when the cancer…